NOD.CB17-Prkdcscid Il2rgtm1Bcgen Il15tm1(IL15)Bcgen Fcgr2btm1Bcgen Fcgr4tm1Bcgen Fcgr3tm1Bcgen Fcgr1tm1Bcgen/Bcgen • 114031
| Product name | huHSC-B-NDG hIL15, FcγR KO mice |
|---|---|
| Catalog number | 114031 |
| Strain name | NOD.CB17-Prkdcscid Il2rgtm1Bcgen Il15tm1(IL15)Bcgen Fcgr2btm1Bcgen Fcgr4tm1Bcgen Fcgr3tm1Bcgen Fcgr1tm1Bcgen/Bcgen |
| Strain background | B-NDG |
| NCBI gene ID | 19090,16186,16168,14129,14130,246256 (Mouse) |
| Aliases | DNA; DOX; dxn; DNA-; XRCC; p460; scid; slip; DNAPK; DNPK1; HYRC1; XRCC7; dxnph; DOXNPH; DNAPDcs;AI326420; AU019811; DNA-PKcs; gc; p64; [g]c; gamm; CD132; gamma(; gamma(c); IL-15; AI503618; CD64; IGGHAFC; AI323638; AV092959; FcgammaRI; AI528646, CD32, F630109E10Rik, Fc[g]RII, FcgRII, Fcgr2, Fcgr2a, Fcr-2, Fcr-3, Ly-17, Ly-m20, LyM-1, Lym-1, fcRII; Fcgr; Fcgam; Fcrl3; CD16-2; FcgRIV; Fcgr3a; FcgammaRIV; 4833442P21Rik |
Antitumor activity of anti-human PD-1 antibody pembrolizumab analog (in-house) in non-small cell lung cancer cell line NCI-H1975 CDX model established with huHSC-B-NDG hIL15, FcγR KO mice. Human CD34+ HSCs (3×104) were intravenously engrafted into B-NDG hIL15, FcγR KO mice within 4-12 hours after being irradiated with 0.9 Gy of X-ray. NCI-H1975 cells (5E6) were subcutaneously inoculated into B-NDG hIL15, FcγR KO mice when the frequency of hCD45+ cells in blood was more than 25%. Mice were grouped when the tumor volume reached approximately 80-100 mm3, at which time they were treated intraperitoneally with pembrolizumab analog with dose and schedule indicated in panel (female, 15-week-old, n=8/9). The results showed that pembrolizumab analog could effectively inhibit tumor growth in lung cancer CDX model established with huHSC-B-NDG hIL15, FcγR KO mice. Values are expressed as mean ± SEM.
